Results 111 to 120 of about 49,135 (301)

Reduced Left Atrial Appendage Flow Velocity as a Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation

Journal of Arrhythmia, Volume 41, Issue 6, December 2025.
Reduced preprocedural LAAFV is associated with adverse long‐term clinical outcomes after AF ablation, including a significantly increased risk of thromboembolic events. ABSTRACT Background Reduced left atrial appendage flow velocity (LAAFV) on transesophageal echocardiography (TEE) is recognized as a predictor of thromboembolic events (TEs) in patients
Shintaro Yamagami, Satoshi Shizuta, Munekazu Tanaka, Shushi Nishiwaki, Takanori Aizawa, Akihiro Komasa, Takashi Yoshizawa, Tetsuma Kawaji, Chihiro Ota, Naoaki Onishi, Yasuhiro Sasaki, Mitsuhiko Yahata, Kentaro Nakai, Mamoru Hayano, Tetsushi Nakao, Koji Hanazawa, Koji Goto, Takahiro Doi, Toshihiro Tamura, Koh Ono, Takeshi Kimura   +20 more
wiley   +1 more source

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry

Therapeutic Advances in Neurological Disorders, 2014
Background: There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding.
Georgios Tsivgoulis, Christos Krogias, Kara A. Sands, Vijay K. Sharma, Aristeidis H. Katsanos, Konstantinos Vadikolias, Sokratis G. Papageorgiou, Ioannis Heliopoulos, Harn Shiue, Athina Mitsoglou, Chrissoula Liantinioti, Dimitrios Athanasiadis, Sotirios Giannopoulos, Charitomeni Piperidou, Konstantinos Voumvourakis, Andrei V. Alexandrov   +15 more
doaj   +1 more source

Antithrombotic Management in Patients With Atrial Fibrillation Following Percutaneous Coronary Intervention: An Updated Clinical Review

Journal of Arrhythmia, Volume 41, Issue 6, December 2025.
In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), antithrombotic management becomes complex to balance ischemic and bleeding risks. In this context, the recent clinical evidence indicates the “less is more” concept in antiplatelet therapy and oral anticoagulation (OAC).
Yuichi Saito, Yoshio Kobayashi
wiley   +1 more source

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

PLoS ONE, 2012
BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You, Kia K N Tsui, Raymond S M Wong, Gergory Cheng   +3 more
doaj   +1 more source

Prior-preconditioned conjugate gradient method for accelerated Gibbs sampling in "large $n$ & large $p$" sparse Bayesian regression

, 2020
In a modern observational study based on healthcare databases, the number of observations and of predictors typically range in the order of $10^5$ ~ $10^6$ and of $10^4$ ~ $10^5$.
Nishimura, Akihiko, Suchard, Marc A.
core   +1 more source

Managing atrial fibrillation in the global community: The European perspective. [PDF]

, 2013
Atrial fibrillation is a common, global problem, with great personal, economic and social burdens. As populations age it increases in prevalence and becomes another condition that requires careful chronic management to ensure its effects are minimised ...
Camm, AJ, Kaba, RA, Sharma, R, Williams, TM   +3 more
core   +1 more source

Impact of Anticoagulation Therapy on Healthcare Utilization in Patients With Epistaxis

Laryngoscope Investigative Otolaryngology, Volume 10, Issue 6, December 2025.
ABSTRACT Objective Epistaxis can occur in individuals on anticoagulants, raising concerns about the potential impact on healthcare utilization. This retrospective analysis aims to compare measures of healthcare utilization of two cohorts: adult epistaxis patients without anticoagulant use compared to adult epistaxis patients on anticoagulants.
Boston Andersen, Alec Kadrie, Meghana Chanamolu, M. Boyd Gillespie   +3 more
wiley   +1 more source

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

Vascular Health and Risk Management, 2013
Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj  

Healthcare utilization and costs for patients initiating Dabigatran or Warfarin

Health and Quality of Life Outcomes, 2017
Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds, Sameer R. Ghate, Richard Sheer, Pranav K. Gandhi, Chad Moretz, Cheng Wang, Stephen Sander, Mary E. Costantino, Srinivas Annavarapu, George Andrews   +9 more
doaj   +1 more source

Oral Anticoagulant Therapy of Patients With Atrial Fibrillation in Cardiology, Internal Medicine, and Surgery: Temporal Trend

MedComm, Volume 6, Issue 12, December 2025.
The multicenter retrospective study reviewed electronic medical records of 70,187 AF patients from 20 hospitals between January 2015 and December 2023. The main findings were that OAC usage was significant increase particularly in cardiology (29.8% pre‐2018 to 68.8% in 2021–2023), while still below 50% in non‐cardiology departments; influent factors ...
Mingjie Lin, He Huang, Juntao Wang, Hui Sun, Xingsheng Xu, Yan Zhang, Wenqiang Han, Min Chen, Kui Dong, Yingcui Wang, Beian You, Guihua Yao, Jingquan Zhong, Congxin Huang   +13 more
wiley   +1 more source